Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis.
Anecdotal case reports suggest tamoxifen as a possible treatment for retroperitoneal fibrosis, but a systematic assessment of its effect is not available. To describe the course and outcomes of patients with nonmalignant retroperitoneal fibrosis treated with tamoxifen. Prospective, consecutive series. Single tertiary care referral center. 19 patients with nonmalignant retroperitoneal fibrosis treated with tamoxifen from April 1998 through April 2005. Tamoxifen, 20 mg orally twice daily. Clinical improvement, laboratory variables, and follow-up computed tomography (CT) and gallium scan findings. Fifteen patients reported substantial resolution of symptoms after a median treatment duration of 2.5 weeks. Erythrocyte sedimentation rate and C-reactive protein also improved. Gallium scanning at follow-up showed incomplete disappearance of pathologic gallium-67 activity. Repeated CT scanning showed slow but steady mass regression in 14 of 15 clinical responders. Five patients failed treatment, including 1 patient who improved clinically. Disease recurred in 1 patient who responded to reintroduction of tamoxifen. One patient developed reversible hepatitis. This small observational study did not have a control group. Tamoxifen may be a viable therapeutic option in the treatment of retroperitoneal fibrosis.